FDA 483 - Emergent Biosolutions LLC - August 16, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Emergent Biosolutions LLC in Canton, MA, a licensed biological drug substance manufacturer, identified two significant issues. The firm failed to make records, specifically security camera footage used in deviation investigations for ACAM2000 bulk drug substance manufacturing, readily available for inspection. Additionally, aseptic process simulation studies did not accurately reflect routine aseptic manufacturing operations, particularly concerning the sterilization process for the ACAM2000 P10 viral process.
ID · d7d52447-f29c-4a6b-a2c9-99be41ce1ae0